Paul F. Lizzul - 22 Dec 2025 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Signature
/s/ Eric Loumeau, Attorney-in-Fact
Issuer symbol
ANAB
Transactions as of
22 Dec 2025
Net transactions value
-$47,250
Form type
4
Filing time
23 Dec 2025, 16:28:44 UTC
Previous filing
07 Jan 2025
Next filing
06 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lizzul Paul F. Chief Medical Officer C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO /s/ Eric Loumeau, Attorney-in-Fact 23 Dec 2025 0001711462

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $27,750 +1,500 +5.6% $18.50 28,467 22 Dec 2025 Direct F1
transaction ANAB Common Stock Sale $75,000 -1,500 -5.3% $50.00 26,967 22 Dec 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Employee Stock Option (right to buy) Options Exercise $0 -1,500 -1.8% $0.000000 83,500 22 Dec 2025 Common Stock 1,500 $18.50 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes the acquisition of 1,324 shares acquired under the Company's ESPP.
F2 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2025.
F3 The stock option is fully vested.
F4 In addition to the remaining options to purchase 83,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 394,810 shares of common stock, which options vest according to their terms.